Dr. Eran Nadav is a Partner and Managing Director at TPG Biotech based in San Francisco, where he focuses on investing in the global pharmaceuticals and biotechnology sectors. Prior to joining TPG in 2007, Eran worked in the pharmaceutical industry, including positions with Eisai and J&J. He holds a PhD in biochemistry, MSc Magna Cum Laude, BSc Magna Cum Laude, and MBA, all from Tel Aviv University. Eran currently serves as Chairman of the Board of Trevi Therapeutics, and on the Boards of Collegium Pharmaceutical ShangPharma (a China-based CRO), Nutrinia and NovaSom. He was the Chairman of the Board of Ultragenyx Pharmaceutical. Other past investments and board roles include JCR Pharm